Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation
Lars Wallentin,Renato D. Lopes,Michael G. Hanna,Laine Thomas,Anne S. Hellkamp,Sunil Nepal,Elaine M. Hylek,Sana M. Al-Khatib,John H. Alexander,Marco Alings,John Amerena,Jack Ansell,Philip E. Aylward,Jozef Bartunek,Patrick J. Commerford,Raffaele De Caterina,Çetin Erol,Veli-Pekka Harjola,Claes Held,John D. Horowitz,Kurt Huber,Steen Husted,Matyas Keltai,Fernando Lanas,Liu Lisheng,John J.V. McMurray,Byung Hee Oh,Mårten Rosenqvist,Witold Rużyłło,Philippe Gabriel Steg,Dragos Vinereanu,Denis Xavier,Christopher B. Granger +32 more
Reads0
Chats0
TLDR
The benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers’ and patients’ predicted quality of international normalized ratio control.Abstract:
Background—In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, ma...read more
Citations
More filters
Journal ArticleDOI
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff,Robert P. Giugliano,Eugene Braunwald,Elaine B. Hoffman,Naveen Deenadayalu,Michael D. Ezekowitz,A. John Camm,Jeffrey I. Weitz,Basil S. Lewis,Alexander Parkhomenko,Takeshi Yamashita,Elliott M. Antman +11 more
TL;DR: A prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials offered clinicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduce the risk of stroke in this patient population.
Journal ArticleDOI
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report
Gregory Y.H. Lip,Amitava Banerjee,Giuseppe Boriani,Chern En Chiang,Ramiz Fargo,Ben Freedman,Deirdre A. Lane,Christian T. Ruff,Mintu P. Turakhia,David J. Werring,Sheena Patel,Lisa K. Moores +11 more
TL;DR: Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF with ≥1 non‐sex CHA2DS2‐VASc stroke risk factor(s), and stroke prevention (ie, oral antICOagulation therapy) is the next step.
Journal ArticleDOI
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.
Sigrun Halvorsen,Dan Atar,Dan Atar,Hongqiu Yang,Raffaele De Caterina,Çetin Erol,David A. Garcia,Christopher B. Granger,Michael G. Hanna,Claes Held,Steen Husted,Elaine M. Hylek,Petr Jansky,Renato D. Lopes,Witold Rużyłło,Laine Thomas,Lars Wallentin +16 more
TL;DR: Apixaban was more effective than warfarin in preventing stroke and reducing mortality across all age groups, and associated with less major bleeding, less total bleeding, and less intracranial haemorrhage regardless of age.
Journal ArticleDOI
Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
Sean D. Pokorney,Sean D. Pokorney,DaJuanicia N Simon,Laine Thomas,Gregg C. Fonarow,Peter R. Kowey,Paul Chang,Daniel E. Singer,Jack Ansell,Rosalia Blanco,Bernard J. Gersh,Kenneth W. Mahaffey,Elaine M. Hylek,Alan S. Go,Jonathan P. Piccini,Jonathan P. Piccini,Eric D. Peterson,Eric D. Peterson +17 more
TL;DR: Among patients with AF in US clinical practices, TTR on warfarin is suboptimal, and those at highest predicted risks for stroke and bleeding were least likely to be in therapeutic range.
Journal ArticleDOI
Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations.
Paul Yates,Victor L. Villemagne,Kathryn A. Ellis,Patricia Desmond,Colin L. Masters,Colin L. Masters,Christopher C. Rowe +6 more
TL;DR: The presence of microbleeds has been suggested to confer increased risk of incident intracerebral hemorrhage – particularly in the setting of anticoagulation – and of complications of immunotherapy for AD.
References
More filters
Journal ArticleDOI
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly,Michael D. Ezekowitz,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +18 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Journal ArticleDOI
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel,Kenneth W. Mahaffey,Jyotsna Garg,Guohua Pan,Daniel E. Singer,Werner Hacke,Günter Breithardt,Jonathan L. Halperin,Graeme J. Hankey,Jonathan P. Piccini,Richard C. Becker,Christopher C. Nessel,John F. Paolini,Scott D. Berkowitz,Robert M. Califf +14 more
TL;DR: In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.
Journal ArticleDOI
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Journal ArticleDOI
Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
A. John Camm,Paulus Kirchhof,Irene Savelieva,Isabelle C. Van Gelder,Gerhard Hindricks,Ottavio Alfieri,Johan De Sutter,Andreas Goette,Stefan H. Hohloser,Piotr Ponikowski,Frans H. Rutten +10 more
TL;DR: Estimates of expected health outcomes for larger societies are included, where data exist, and the level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to pre-defined scales.
Journal ArticleDOI
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
TL;DR: An updated meta-analysis of all currently available randomized trials that extends observations about the efficacy and safety of antithrombotic therapies for preventing stroke in patients who have atrial fibrillation is presented.
Related Papers (5)
Dabigatran versus warfarin in patients with atrial fibrillation
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Edoxaban versus warfarin in patients with atrial fibrillation
Robert P. Giugliano,Christian T. Ruff,Eugene Braunwald,Sabina A. Murphy,Stephen D. Wiviott,Jonathan L. Halperin,Albert L. Waldo,Michael D. Ezekowitz,Jeffrey I. Weitz,Witold Rużyłło,Mikhail Ruda,Yukihiro Koretsune,Joshua Betcher,Minggao Shi,Laura T. Grip,Laura T. Grip,Shirali P. Patel,Indravadan Patel,James J. Hanyok,Michele Mercuri,Elliott M. Antman,Elliott M. Antman,Abstr Act,Abstr Act +23 more